News Release

Frost & Sullivan recognizes Insilico as innovation leader in drug discovery

Grant and Award Announcement

InSilico Medicine

Frost & Sullivan Recognizes Insilico as Innovation Leader in Drug Discovery

image: Frost & Sullivan recognizes Insilico as Innovation leader in drug discovery highlighting it as a technology pioneer in this industry. view more 

Credit: Insilico

April 30, 2020 - Today Insilico Medicine has announced that Frost & Sullivan named it as a top innovator in drug discovery, highlighting it as a technology pioneer in this industry.

Generative AI is an emerging technology in both chemistry and biology. Insilico Medicine has been working in these areas since 2015, and holds the critical intellectual property in generative biology for generation of synthetic biological data, target discovery, and cross-tissue and cross-species analysis; generative chemistry for generation of novel molecules, and generative medicine for prediction of clinical trials outcomes. According to recent legal opinions, drugs generated using AI may be classified as being invented by AI. Insilico published its first peer-reviewed papers in this area in 2016, and multiple experimental proofs of concept for JAK3 and DDR1 kinases with many other targets being pursued internally.

The company generated and released a range of molecules targeting COVID-19 protease generated in 4 days. Generative biology technology for the target discovery has been developed and utilized internally since 2015, and the first landmark experiment in target discovery is expected to be published in 2020.

"Insilico Medicine is a true innovator and visionary in the application of AI for novel product discovery and precision medicine. The deep generative models based on neural networks, Generative Tensorial Reinforcement Learning (GENTRL) models developed by the company generates and tests new leads with breakthrough productivity over conventional industry benchmarks." said Amol Jadhav, PhD, Industry Analyst at Frost & Sullivan. "Frost & Sullivan is pleased to include Insilico Medicine in recognition of its pioneering research, validated full stack technology, growing pipeline of molecules, extensive portfolio and commitment toward high-profile partnerships".

"I would like to congratulate my global teams on their tireless efforts and excellence in both AI and drug discovery that are now recognized by Frost & Sullivan. For five years we made bets on disruptive technologies with very limited resources and often struggled. But now these bets paid off and we are getting a new software suite we refer to as the Pharmaceutical Operating System to be released this year," said Alex Zhavoronkov, PhD, co-founder and CEO of Insilico Medicine.

Insilico Medicine has been at the forefront of the competition and has established collaborations and partnerships with over 150 academic and industry partners worldwide.


About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 80 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website

Media Contact

For further information, images or interviews, please contact:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.